Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters
We investigated the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the resistance of dyslipidemic hamsters to statin-induced LDL-cholesterol (LDL-C) reduction and the molecular mechanism by which statins modulated PCSK9 gene expression in vivo. We utilized the fructose diet-induced...
Main Authors: | Bin Dong, Minhao Wu, Hai Li, Fredric B. Kraemer, Khosrow Adeli, Nabil G. Seidah, Sahng Wook Park, Jingwen Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2010-06-01
|
Series: | Journal of Lipid Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0022227520410235 |
Similar Items
-
Assessment of the Efficacy of Lowering LDL Cholesterol with Rosuvastatin 10 mg in Four Korean Statin Benefit Groups as per ACC/AHA Guidelines (NewStaR4G)
by: Kyung-Jin Kim, et al.
Published: (2020-03-01) -
Correlation of compliance to statin therapy with lipid profile and serum HMGCoA reductase levels in dyslipidemic patients
by: Abhinav Grover, et al.
Published: (2017-01-01) -
LDL particle size and reactive oxygen metabolites in dyslipidemic patients
by: Kazuhiko Kotani, et al.
Published: (2012-01-01) -
Serum sdLDL-C and cellular SREBP2-dependent cholesterol levels: Is there a challenge on targeting PCSK9?
by: Soltanmohammadi Elham, et al.
Published: (2016-01-01) -
Asociation of PCSK9 with Low Density Lipoproteins (LDL) in the Regulation of LDL-Cholesterol Levels
by: Sarkar, Samantha Khadija
Published: (2015)